Adverse Events WHO Grades 3 and 4 During Induction and Consolidation
| Events . | Induction . | Consolidation . | ||
|---|---|---|---|---|
| TAD-TAD . | TAD-HAM . | TAD-TAD . | TAD-HAM . | |
| Nausea/vomiting | 17 (13-21) | 22 (18-27) | 16 (11-22) | 9 (5-13) |
| Stomatitis | 10 (7-14) | 9 (6-12) | 1 (0-4) | 3 (1-6) |
| Diarrhea | 12 (9-16) | 10 (7-14) | 3 (1-7) | 4 (2-8) |
| Hemorrhage | 11 (8-15) | 10 (7-14) | 2 (1-5) | 4 (2-8) |
| Infection | 33 (28-38) | 40 (35-45) | 11 (7-16) | 11 (6-15) |
| Cardiac events | 8 (5-11) | 6 (4-9) | 2 (1-5) | 1 (0-3) |
| CNS toxicity | 1 (0-3) | 2 (1-4) | 0 (0-2) | 1 (0-3) |
| Events . | Induction . | Consolidation . | ||
|---|---|---|---|---|
| TAD-TAD . | TAD-HAM . | TAD-TAD . | TAD-HAM . | |
| Nausea/vomiting | 17 (13-21) | 22 (18-27) | 16 (11-22) | 9 (5-13) |
| Stomatitis | 10 (7-14) | 9 (6-12) | 1 (0-4) | 3 (1-6) |
| Diarrhea | 12 (9-16) | 10 (7-14) | 3 (1-7) | 4 (2-8) |
| Hemorrhage | 11 (8-15) | 10 (7-14) | 2 (1-5) | 4 (2-8) |
| Infection | 33 (28-38) | 40 (35-45) | 11 (7-16) | 11 (6-15) |
| Cardiac events | 8 (5-11) | 6 (4-9) | 2 (1-5) | 1 (0-3) |
| CNS toxicity | 1 (0-3) | 2 (1-4) | 0 (0-2) | 1 (0-3) |
Values are percentages. In parentheses are 95% CI.